 |
 |

Superselective Neck Dissection After ChemoradiationFeasibility Based on Clinical and Pathologic Comparisons
K. Thomas Robbins, MD;
Kerwin Shannon, MD;
Francisco Vieira, MD
Arch Otolaryngol Head Neck Surg. 2007;133(5):486-489.
Objective To determine whether superselective neck dissection (removal of 2 or less contiguous neck levels) is effective salvage surgery for patients with residual single-level adenopathy after concomitant intra-arterial cisplatin and radiotherapy.
Design Analysis of prospectively collected data.
Subjects The study group comprised 177 patients (239 heminecks) with N+ disease.
Interventions Intra-arterial treatment with cisplatin (150 mg/m2) on days 1, 8, 15, and 22 and radiation therapy (2 Gy/d) 5 times per week for 7 weeks. Comparisons were made between neck-level–specific disease at restaging and pathologic disease after neck dissection.
Results Tumor sites included oropharynx (n = 81), hypopharynx (39), larynx (n=27), oral cavity (n = 19), and other (n = 11). Response of nodal disease based on clinical evaluation was as follows: complete response, 89 patients (50%); partial response, 81 patients (46%); progressive disease, 4 patients (2%); and unevaluable, 3 patients (2%). Of the 89 patients whose necks were restaged as a partial response, 73 had clinical evidence of residual adenopathy involving only 1 neck level. Within this subset, 54 patients (57 heminecks) subsequently underwent a salvage neck dissection, for which comparisons were made between the restaging evidence of residual adenopathy and the pathologic findings that were specific for each neck level. Only 2 of the 54 patients had evidence of pathologic disease extending beyond the single neck level: one had disease in a contiguous neck level, and the other had disease in a noncontiguous level. The use of superselective neck dissection with removal of only 2 contiguous neck levels would have encompassed known disease in all but 1 patient.
Conclusion Superselective neck dissection is feasible after this specific chemoradiation protocol has been administered to patients with persistent nodal disease that is confined to 1 level.
Author Affiliations: Division of Otolaryngology–Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield (Dr Robbins); Sydney Head and Neck Cancer Institute, Sydney, Australia (Dr Shannon); and Department of Otolaryngology–Head and Neck Surgery, University of Tennessee, Memphis (Dr Vieira).
|